Innovative leads with initial proof-of-concept

The LDC provides biopharmaceutical companies with unique access to pharmaceutical leads based on the most innovative research findings from leading research institutions. All leads come with proof-of-concept in animal models, solid IP protection and professional in-depth data packages, enabling a smooth transition into an industry partner's lead optimization and drug development environment.

 

For projects originating from Max Planck Institutes and funded by the Max-Planck Society, Max Planck Innovation will be your partner for structuring licensing or co-development deals.

 

For all other projects (non-Max-Planck projects), negotiations will be led by the respective project owner or the technology transfer agent in charge. LDC can operate as a fully flexible partner regarding partnering and licensing, but will not drive the projects beyond a nomination to preclinical development.